Emily K. Sims

Physician scientist at Indiana University

[Emily K. Sims @EmKSims]

As always, such a pleasure to work with Erin Templeman from the @UniofExeter team, @RAOram, and Lauric Ferrat, as well as an excellent team of collaborators like @cevansmo @catespeake and others who are not on this platform. @IUSweetTweets

[Emily K. Sims @EmKSims]

3. Risk scores like HbA1c and metabolic indices performed better in adults
4. Unique patterns suggest a need for age-tailored screening and follow-up

[Emily K. Sims @EmKSims]

2. Unlike those were were single Ab positive or met stage 1 T1D criteria, adults with stage 2 T1D at screening progressed at the same rate as children (78% in 5 years)

[Emily K. Sims @EmKSims]

Super excited this paper on islet autoantibody positive adults is finally online- we analyzed screening and #T1D progression in 100K adult relatives screened as part of @T1D_TrialNet . Available at: https://t.co/HirR35TFE7

[Emily K. Sims @EmKSims]

We found important differences exist in screening and progression amongst children and adults. For example:
1. Adults were more likely to screen single Ab positive compared to kids

[Emily K. Sims @EmKSims]

Really excited to share this super translational project from rockstar @chaipoorva ! Islets and T cells and EVs- what more could you want ❤️?

[Diabetologia @DiabetologiaJnl]

Beta cell extracellular vesicles carry PD-L1 and suppress CD8+ T cells. EV PD-L1 is increased in AAB+ individuals, correlating with residual beta cell function. Potential #biomarker for #T1D heterogeneity. #Diabetes @IUSweetTweets @emksims @chaipoorva https://t.co/EODcGN0O5d

[Emily K. Sims @EmKSims]

Should be a good one!

[Dr. Carmella EvansMolina @cevansmo]

Join @TeresaMastracci , @claus_jorgensen , Maureen Gannon, and me at the Gordon Research Conference (GRC) on Pancreatic Diseases in June - "where the endocrine and exocrine pancreas meet". Registration is now open https://t.co/b8sBXNiglF

[Emily K. Sims @EmKSims]

Excited to work with this awesome team!

[Erin Templeman @erinltempleman]

Thrilled to share our study: Risk associated with single autoantibody shifts after age 10, with men at higher T1D risk. Thanks to @EmKsims, @RAOram, @FerratLauric, and @T1D_TrialNet for their support. Read full press release here: https://t.co/MKgNbbL7Tm #T1D #DiabetesResearch

[Med Learning Group @MLG_CME]

👋Meet us in #Indianapolis for our Complimentary CE Dinner Meeting on #Type1Diabetes on Monday, June 17th!

➡️ https://t.co/jq0yq7ieID

@EmKSims

#Diabetes #ContinuingEducation #HealthcareProfessionals #Continuingprofessionaleducation #FOAMed #endocrinology

[Emily K. Sims @EmKSims]

@IUSweetTweets @WIELDvoice @IUMedSchool @EliLillyandCo @DoctorDiMeglio @cevansmo So thankful to have had the chance to learn from both of these superstars 😍😍😍

[Center for Diabetes and Metabolic Diseases @IUSweetTweets]

Congrats to the global experts recognized as 2024 @WIELDvoice Trailblazers, especially @IUMedSchool Drs. Evans-Molina & DiMeglio and @EliLillyandCo Dr. Gimeno. We're proud and fortunate to have many female leaders in diabetes making an impact in Indiana! https://t.co/P4WV3K99hN

[Emily K. Sims @EmKSims]

Great work by @JacobsenLM and @Heba_T1D supporting the idea that metabolic endpoints can give us a quick readout of T1D disease modification. And we know based on @DrPeteTaylor and Colin Dayan's data that these changes have clinical relevance for our patients with T1D!

[Diabetes Care, an ADA research journal 🌟 @DiabetesCareADA]

@T1D_TrialNet identifies earlier trial end points that demonstrate a beneficial treatment effect at 6 months and predict benefit out to 12 months. This could allow for shorter early phase trials or adaptive designs. @ADA_Pubs

Read Here➡️https://t.co/ZgSxKOdOhX

[Emily K. Sims @EmKSims]

@IUSweetTweets @IUMedSchool @JDRF @DoctorDiMeglio Super excited to have these two rockstars in our group @IUSweetTweets @DoctorDiMeglio !

[Emily K. Sims @EmKSims]

Super excited for one of the best meetings of the year!

[Immunology of Diabetes Society @ImmDiabSoc]

Registration is now open to attend the 20th Immunology of Diabetes Society Congress in Bruges, Belgium on Nov 4-8, 2024! Learn more about this year's program, register and submit an abstract by visiting https://t.co/i3FZwiZdVh.

#T1DResearch #DiabetesResearch #IDS2024

[Emily K. Sims @EmKSims]

@BesserBesser Super exciting! #thefutureisnow

[Emily K. Sims @EmKSims]

#ibjhealthcareheroes

[Emily K. Sims @EmKSims]

Do metabolic measures perform similarly for predicting T1D vs. assessing immunotherapy? Not necessarily. However, combined glucose and C-peptide measures were consistent performers for both purposes. Check out at https://t.co/HXp2g2GZvP ! @T1D_TrialNet @IUSweetTweets

[Dr. Jessica Dunne @jessdunnephd]

Attending #nPOD2024! Come to our @WIELDvoice breakfast panel where we discuss opportunities & barriers to leadership.

[Emily K. Sims @EmKSims]

So excited to see where this important work goes!

[Dr. Carmella EvansMolina @cevansmo]

Thrilled to represent @IUDeptPeds and co-lead the newly funded Heartland Children’s Nutrition Collaborative with @ssimsek22 from @PurdueFoodSci. We're extremely grateful for the Ricks Family Foundation's investment in pediatric health and precision nutrition research

[Emily K. Sims @EmKSims]

@rmirmira @SarahTersey @NIDDKgov 🙌🙌🙌 @SarahTersey